These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24934887)

  • 1. Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan.
    Izumikawa K; Watanabe A; Miyashita N; Ishida T; Hosono H; Kushimoto S; Kohno S
    J Infect Chemother; 2014 Sep; 20(9):549-57. PubMed ID: 24934887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan.
    Izumikawa K; Watanabe A; Miyashita N; Ishida T; Hosono H; Kushimoto S; Kohno S
    J Infect Chemother; 2014 Sep; 20(9):541-8. PubMed ID: 24934886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nationwide, multicenter survey on the efficacy and safety of piperacillin for adult community-acquired pneumonia in Japan.
    Yamamoto Y; Watanabe A; Goto H; Matsushima T; Abe S; Aoki N; Shimokata K; Mikasa K; Niki Y; Kohno S
    J Infect Chemother; 2012 Aug; 18(4):544-51. PubMed ID: 22618270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
    Uncu H; Colakoğlu S; Turunç T; Demiroğlu YZ; Arslan H
    Mikrobiyol Bul; 2007 Jul; 41(3):441-6. PubMed ID: 17933256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Discussions on PRSP and BLNAR].
    Tajima T; Meguro H; Akita H; Iwata T
    Jpn J Antibiot; 2001 May; 54 Suppl B():103; discussion 104-6. PubMed ID: 12638161
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
    Kohno S; Tateda K; Kadota J; Fujita J; Niki Y; Watanabe A; Nagashima M
    J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of twice-daily administration of CTDR].
    Ogata H
    Jpn J Antibiot; 2001 May; 54 Suppl B():98. PubMed ID: 12638156
    [No Abstract]   [Full Text] [Related]  

  • 12. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
    Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
    Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and bacteriological evaluation of ceftriaxone (CTRX) dosed once daily in children with community-acquired pneumonia].
    Toyonaga Y; Kanemura H; Kitano M; Mitsui Y; Ishihara T; Hoshiai M; Ohno R
    Jpn J Antibiot; 1999 Apr; 52(4):322-32. PubMed ID: 10396689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic non-susceptibility among Streptococcus pneumoniae and Haemophilus influenzae isolates identified in African cohorts: a meta-analysis of three decades of published studies.
    Ginsburg AS; Tinkham L; Riley K; Kay NA; Klugman KP; Gill CJ
    Int J Antimicrob Agents; 2013 Dec; 42(6):482-91. PubMed ID: 24139883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical studies of garenoxacin.
    Takagi H; Tanaka K; Tsuda H; Kobayashi H
    Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
    Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
    East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.